SubHero Banner

Opzelura (ruxolitinib) – New drug approval

September 21, 2021 - Incyte announced the FDA approval of Opzelura (ruxolitinib) cream, for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Download PDF